Detalhe da pesquisa
1.
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Lancet
; 399(10319): 36-49, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34883053
2.
Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
Lancet
; 398(10318): 2277-2287, 2021 12 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34774197
3.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Lancet
; 397(10282): 1351-1362, 2021 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33798499
4.
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Lancet
; 398(10303): 856-869, 2021 09 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34370971
5.
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Lancet
; 397(10269): 99-111, 2021 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33306989
6.
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Lancet
; 397(10277): 881-891, 2021 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617777
7.
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Lancet
; 396(10249): 467-478, 2020 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32702298
8.
The effect of chronic cytomegalovirus infection on pneumococcal vaccine responses.
J Infect Dis
; 209(10): 1635-41, 2014 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24302755
9.
Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial.
Vaccine
; 42(12): 2945-2950, 2024 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38580516
10.
Delivering COVID-19 vaccine trials at speed: the implementation of a phase IV UK multi-centre randomised controlled trial to determine safety and immunogenicity of COVID-19 vaccines co-administered with seasonal influenza vaccines (ComFluCOV).
Trials
; 25(1): 39, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38212836
11.
Working under short timescales to deliver a national trial: a case study of the ComFluCOV trial from a statistician's perspective.
Trials
; 25(1): 79, 2024 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38263245
12.
Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells.
J Infect Dis
; 205(9): 1408-16, 2012 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22457293
13.
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
J Infect
; 87(3): 242-254, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37406777
14.
Prolonged T-cell activation and long COVID symptoms independently associate with severe COVID-19 at 3 months.
Elife
; 122023 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37310006
15.
Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.
Lancet Infect Dis
; 22(12): 1716-1727, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36075233
16.
Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults.
J Infect
; 85(3): 306-317, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35718205
17.
Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial.
Clin Transl Sci
; 15(2): 524-534, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34670021
18.
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Lancet Respir Med
; 10(11): 1049-1060, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35690076
19.
A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults.
Clin Infect Dis
; 52(6): 736-42, 2011 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21367726
20.
Acute necrotizing sinusitis caused by Staphylococcus lugdunensis.
J Clin Microbiol
; 49(7): 2740-2, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21593256